软肝抗纤方对肝纤维化实验大鼠TGF-β/Smad信号转导通路的影响  

The Effect of Ruangan Kangxian Prescription on TGF-β/Smad Pathway of Liver Fibrosis Rat

作　　者：刘益平 

机构地区：[1]广东省广州市萝岗区九佛医院,510555

出　　处：《中国医药指南》2010年第16期50-52,共3页Guide of China Medicine

摘　　要：目的为进一步阐明TGF-β/Smad信号通路的结构、功能及其与肝纤维化的关系提供理论依据。方法以四氯化碳和二甲基亚硝胺致的两种肝纤维化大鼠模型为基础,用软肝抗纤方治疗肝纤维化,研究模型组和给药组与信号转导系统有关的信号转导分子(TGF-β1、Smad3、Smad7和SARA等)在肝纤维化的变化特点和功能作用。结果中药预防组与中药治疗组较之两组模型组,在肝脏羟脯氨酸含量,TGF-β1、Smad3、Smad7和SARA蛋白的表达,TGF-β1、Smad3、Smad7 mRNA含量等指标上具有显著差异,中药预防组与中药治疗组较之空白对照组无显著差异。结论软肝抗纤方在动物模型对肝纤维化具有一定作用,可做进一步的临床研究。Objective To explore the structure and function of TGF-β/Smad pathway,and the relationship of it with liver fibrosis.Methods Use CCl4 and DMN induced liver fibrosis rat and model,and treat it by Ruangan Kangxian prescription,study the function and changes between model group and therapy group at relative pathway such as TGF-β1,Smad3,Smad7 and SARA.Results There are significant differences（P 0.05） between treated group and model group at Hyp ingredient and TGF-β1,Smad3,Smad7,SARA protein expression and TGF-β1,Smad3,Smad7 mRNA.The difference between treated group and control group groups were had no significant differences（P0.05）.Conclusion Ruangan Kangxian prescription show reasonable effect on animal model,and can be used to further clinical study.

关 键 词：软肝抗纤方 TGF-β/Smad信号转导 肝纤维化 

分 类 号：R575[医药卫生—消化系统]